Novo Nordisk's Alzheimer's Drug Trial Halt Sends Shares Plummeting

Novo Nordisks Alzheimers Drug Trials Halted, Shares Plummet: Despite low odds, Novo Nordisk pursued Alzheimers treatment with semaglutide, but trials yielded no success, leading to a significant drop in shares. The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.